RecruitingNot ApplicableNCT06915974

Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients


Sponsor

Ain Shams University

Enrollment

70 participants

Start Date

Jan 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.


Eligibility

Min Age: 25 YearsMax Age: 60 Years

Inclusion Criteria4

  • Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence.
  • patients with burn percentage of 25% to 50% of total body surface area
  • patients with second to third degree burns
  • ASA 1 and ASA 2 patients

Exclusion Criteria4

  • Burn percentage more than 50% or less than 25% of total body surface area
  • Having autoimmune diseases
  • Cancer patients
  • ASA 3 and ASA 4 patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTInterleukin 6

Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10


Locations(1)

Ain Shams University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06915974


Related Trials